Amendments to the Specification:

On page 24, just before paragraph [0095], amend the section header as follows:

e. Histological Analyses of Spinal [[Chord]] Cord from EAE Mice following Oral Administration of IFNτ.

Amend paragraph [0115] as follows:

[0115] Another suitable formulation is a protective dosage form that protects the protein for survival in the stomach and intestines until absorbed by the intestinal mucosa. Protective dosage forms for proteins are known in the art, and include enteric coatings and/or mucoadhesive polymer coatings. Examplary mucoadhesive polymer formulations include ethyl cellulose, hydroxypropylmethylcellulose, Eudragit®, carboxyvinly polymer, carbomer, and the like. A dosage form designed for administration to the stomach via ingestion for delivery of IFNτ in an active form to the intestinal tract, and particularly to the small intestine, is contemplated. Alternatively, IFNτ can be co-administered with protease inhibitors, stabilized with polymeric materials, or encapsulated in a lipid or polymer particle to offer some protection from the stomach and/or intestinal environment.

Delete paragraph number [0155].

Amend paragraph [0136] as follows:

[0136] On day one, one bottle of IFNτ (SEQ ID NO:[[4]] 3) was removed from the refrigerator and the patient self-administered the proper volume of test material according to Table 2. IFNτ (SEQ ID NO:2) may also be prepared and administered in the same manner.